Pancreatic Cancer Research

ResearcherEast Carolina UniversityNo recent work listed

James Andrew McCubrey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6027-3156; OpenAlex author ID A5030391285. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
8
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 5 papers · 2023: 1 paper

Papers 16

  1. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies. Co-author DOI 10.1016/j.jbior.2022.100917↗
  2. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Last author DOI 10.1016/j.jbior.2021.100840↗
  3. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1… Co-author DOI 10.18632/aging.204038↗
  4. APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells. Co-author DOI 10.3390/biom12020276↗
  5. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. Last author DOI 10.3390/cells11050794↗
  6. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Co-author DOI 10.3390/cells11142155↗
  7. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Last author DOI 10.1016/j.jbior.2020.100780↗
  8. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic c… Last author DOI 10.1016/j.jbior.2019.100672↗
  9. TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer. Last author DOI 10.18632/aging.102776↗
  10. Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Last author DOI 10.1016/j.jbior.2018.10.003↗
  11. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutrac… Last author DOI 10.1016/j.jbior.2019.03.002↗
  12. Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Last author DOI 10.1016/j.jbior.2019.04.003↗
  13. Metformin influences drug sensitivity in pancreatic cancer cells. Last author DOI 10.1016/j.jbior.2018.02.002↗
  14. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Last author DOI 10.1016/j.jbior.2018.06.002↗
  15. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Last author DOI 10.1016/j.jbior.2015.06.003↗
  16. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. First author DOI 10.1016/j.jbior.2014.05.001↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephen Lee Abrams · 14 shared papers, 2015–2023 · strength 1.51
  2. Melchiorre Cervello · 12 shared papers, 2015–2023 · strength 1.22
  3. Shaw M. Akula · 8 shared papers, 2019–2022 · strength 0.93
  4. Agnieszka Gizak · 9 shared papers, 2018–2022 · strength 0.91
  5. Saverio Candido · 9 shared papers, 2015–2022 · strength 0.73
  6. Przemysław Duda · 3 shared papers, 2022 · strength 0.43
  7. Marco Falasca · 2 shared papers, 2018–2020 · strength 0.15
  8. Timothy Louis Fitzgerald · 2 shared papers, 2014–2015 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.